Post

89bio wins EMA priority status for MASH candidate pegozafermin

The European Medicine’s Agency (EMA) has granted priority medicines (PRIME) status to 89bio’s pegozafermin, a drug being evaluated to treat …

Pfizer’s Velsipity UK approval raises competition in the ulcerative colitis market

The recent approval of Pfizer’s oral drug, Velsipity (etrasimod), by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for …

Cleerly touts new data for AI cardiovascular software

Digital healthcare company Cleerly has announced that positive data from two studies investigating its AI-QCT ISCHEMIA software device has been …

Implantica gears up for FDA approval of acid reflux device

Implantica has started the premarket approval process with the US Food and Drug Administration (FDA) for its gastroesophageal reflux disease …

Oncology in 2024: The clinical trial trends reshaping the role of CROs

Oncology is the most active area in clinical trials globally this year, as more resources than ever are being dedicated …